The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesWB: Use at a concentration of 1-5 µg/ml.
This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.
Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
RelevanceApoptosis is related to many diseases and induced by a family of cell death receptors and their ligands. Cell death signals are transduced by death domain containing adapter molecules and members of the caspase family of proteases. These death signals finally cause the degradation of chromosomal DNA by activated DNase. DFF45/ICARD has been identified as inhibitor of caspase activated DNase DFF40/CAD. DFF45 related proteins CIDE A and CIDE B (for cell death inducing DFF like effector A and B) were recently identified. CIDE contains a new type of domain termed CIDE N, which has high homology with the regulatory domains of DFF45/ICAD and DFF40/CAD. Expression of CIDE A induces DNA fragmentation and activates apoptosis, which is inhibited by DFF45. CIDE A is a DFF45 inhibitable effector that promotes cell death and DNA fragmentation. CIDE A is expressed in many tissues.